Paul M. Aebersold, Ph.D. Joins Board of Directors at NanoIVD, Inc.

2009-10-28 17:41:22 - NanoIVD, Inc. today announced that Paul M. Aebersold, Ph.D. has been appointed to the Company's Board of Directors.

Dr. Aebersold advises pharmaceutical and biotechnology companies on regulatory strategy for product development.

He earned an undergraduate degree in physics and a doctorate degree in biophysics from the University of California, Berkeley. He did post-doctoral research at the Sloan Kettering Institute, the Department of Molecular Biology at U.C. Berkeley, and at the Harvard University School of Public Health. He then

worked at Cetus Corporation, an early biotechnology company, on biological characterization of recombinant cytokines and at the National Cancer Institute on immunologic therapy of cancer.

He subsequently worked for 16 years at the Food and Drug Administration in the Center for Biologics Evaluation and Research, initially on INDs for cytokines, somatic cell therapies, and gene therapies, later on INDs and BLAs for immune globulins, clotting factors, and oxygen therapeutics and on IDEs and PMAs for combination biologic/device products. He made presentations at the Blood Products Advisory Committee and at FDA-sponsored workshops on oxygen therapeutics (blood substitutes) and immune globulins and he participated in the drafting of guidance documents for fibrin sealants, oxygen therapeutics, and trials run under the provisions for exception from informed consent. He received five Certificates of Appreciation and 12 Awards and while at the Food and Drug Administration, including a Secretary's Award for Distinguished Service from the Department of Health and Human Services.

"We are very pleased to welcome an experienced regulatory executive to our Board of Directors," stated Sunnie Kim, NanoIVD, Inc.'s President & CEO. "We believe our Company is poised for success in these three business segments: cancer IVD point of care, companion diagnostics development, and technology licensing, and the counsel of our new Director should prove invaluable in the accomplishment of our strategic objectives."

About NanoIVD, Inc.
The NanoIVD develops and manufactures sensor and portable instruments for biological research and clinical sample testing. The company has proprietary technologies for a point-of-care analyzer and single-use test cartridge system that uses very little body fluid to achieve minimally invasive health monitoring, early disease detection, and treatment-effectiveness monitoring. NanoIVD technologies are intended to offer versatile, real-time detection, rapid results, and achieve high sensitivity and specificity single or multiplex genomic, proteomic and cytology target detection in a single test run.

The Company is headquartered in Los Angeles, California. To learn more about NanoIVD, Inc. please visit www.nanoivd.com.

Forward-Looking Statements
This document may include statements that constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect", "anticipate", or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the ability to negotiate and execute licenses and contracts in connection with the Company's technologies and products; obtain patents that provide commercially significant protection for its technologies; and the need for substantial additional capital to fund development of products and to continue operations.

For Additional Information, Please Contact: Sunnie Kim, President & CEO, at (310) 529-1188 or via email at s.kim@nanoivd.com or Investor Relations, at ir@nanoivd.com.

By making these forward-looking statements, NanoIVD undertakes no obligation to update these statements for revisions or changes in the future.